Sanofi (NASDAQ:SNY) Shares Bought by Stablepoint Partners LLC

Stablepoint Partners LLC lifted its stake in shares of Sanofi (NASDAQ:SNY) by 4.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 25,063 shares of the company’s stock after purchasing an additional 1,170 shares during the period. Stablepoint Partners LLC’s holdings in Sanofi were worth $1,209,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in SNY. Lantz Financial LLC boosted its stake in Sanofi by 6.7% during the fourth quarter. Lantz Financial LLC now owns 8,277 shares of the company’s stock worth $399,000 after buying an additional 520 shares during the last quarter. Sound Income Strategies LLC raised its holdings in shares of Sanofi by 156,520.9% during the 4th quarter. Sound Income Strategies LLC now owns 67,347 shares of the company’s stock worth $3,248,000 after acquiring an additional 67,304 shares during the period. Brighton Jones LLC boosted its position in shares of Sanofi by 52.6% during the 4th quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock valued at $261,000 after acquiring an additional 1,869 shares during the last quarter. Janney Montgomery Scott LLC increased its position in Sanofi by 5.9% during the fourth quarter. Janney Montgomery Scott LLC now owns 327,631 shares of the company’s stock worth $15,802,000 after purchasing an additional 18,279 shares during the last quarter. Finally, SG Americas Securities LLC raised its stake in Sanofi by 19.5% during the fourth quarter. SG Americas Securities LLC now owns 18,008 shares of the company’s stock worth $869,000 after purchasing an additional 2,940 shares during the period. 14.04% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Stock Up 1.0 %

Shares of NASDAQ:SNY opened at $52.48 on Monday. The business has a 50-day moving average price of $48.70 and a 200 day moving average price of $52.20. Sanofi has a 12-month low of $45.22 and a 12-month high of $58.97. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The company has a market capitalization of $133.19 billion, a price-to-earnings ratio of 26.78, a PEG ratio of 1.19 and a beta of 0.57.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.22 by $1.35. The business had revenue of $13.44 billion for the quarter, compared to the consensus estimate of $16.59 billion. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The business’s revenue was up 12.3% on a year-over-year basis. During the same period in the previous year, the firm earned $2.55 EPS. Sell-side analysts expect that Sanofi will post 3.82 EPS for the current year.

Wall Street Analyst Weigh In

Separately, StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.